Comparing two tablet forms of a study drug in healthy people
Treatments studied
This study compares how two different tablet versions of a combination of vicadrostat and empagliflozin are absorbed by the body. It is for healthy volunteers to see which form works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old
- Your body mass index (BMI) is between 18.5 and 29.9
- You are generally healthy, with no significant medical conditions
- You have normal blood pressure, heart rate, and electrocardiogram (heart test) results
- You are willing to sign a consent form to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different versions of an injected study drug (survodutide) to see how they are absorbed by the body. It is open to healthy people and people with overweight or obesity, and it may help researchers find a better way to deliver this treatment.
This trial compares two different forms of a medication to see how they are absorbed and processed by the body and to check that they are safe. It is an early-stage study in healthy volunteers.
This study tests a new pill called vicadrostat taken with another medicine (empagliflozin) to see if it helps people with type 2 diabetes, high blood pressure, and heart disease. It may reduce the risk of heart problems, but you must not have had heart failure or use certain other heart medications.
This study tests if a new medicine (vicadrostat) works differently than an older one (spironolactone) in people with heart failure or heart disease and reduced kidney function. It aims to understand how they affect proteins in the blood and kidney blood flow.
This study tests whether adding a new study drug called vicadrostat to the standard heart failure medicine empagliflozin helps people with heart failure. It may be a good option if you have heart failure with preserved pumping function and are not already on a medicine called an MRA.
This trial tests a new drug called vicadrostat combined with another drug, empagliflozin, for people with heart failure and a weak heart pump. It aims to see if this combination helps improve symptoms and outcomes.
Hear when a new Healthy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.